ADVM · As filed with the SEC
Adverum Biotechnologies income statement, by quarter
The statement as Adverum Biotechnologies presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Statements of Operations and Comprehensive Loss · USD thousands, except per-share amounts; shares in thousands
| USD thousands, except per-share amounts; shares in thousands | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 | Q3 2024† 3 months ended Sep 30, 2024 | Q2 2024† 3 months ended Jun 30, 2024 | Q1 2024 3 months ended Mar 31, 2024 | Q4 2023† 3 months ended Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|
| License revenue | 0 | — | — | 0† | 1,000 | 0 | 0 | 0† |
| Operating expenses: | ||||||||
| Research and development | 38,913 | 37,125 | 28,747 | 24,095† | 20,439 | 17,097 | 15,410 | 15,468† |
| General and administrative | 9,110 | 12,730 | 19,474 | 18,523† | 9,782 | 3,785 | 11,429 | 6,529† |
| Total operating expenses | 48,023 | 49,855 | 48,221 | 42,618† | 30,221 | 20,882 | 26,839 | 21,997† |
| Operating loss | (48,023) | (49,855) | (48,221) | (42,618)† | (29,221) | (20,882) | (26,839) | (21,997)† |
| Other income, net | — | — | 1,202 | — | 2,087 | 2,406 | 2,052 | 1,311† |
| Other income, net | 371 | 664 | — | 1,687† | 2,087† | 2,406† | — | 1,311† |
| Net loss before income taxes | — | — | — | (60,530)† | (27,134) | (18,476) | (24,787) | (20,686)† |
| Income tax benefit | — | — | — | 0† | 0 | 0 | 0 | 1,133† |
| Net loss | (47,652) | (49,191) | (47,019) | (40,931)† | (27,134) | (18,476) | (24,787) | (19,553)† |
| Other comprehensive gain (loss): | ||||||||
| Net unrealized loss on marketable securities | — | (11) | (53) | (93)† | 241 | (2) | (41) | 54† |
| Net unrealized gain (loss) on marketable securities | 5 | — | — | — | — | — | — | — |
| Foreign currency translation adjustment | 6 | 18 | 2 | (46)† | 16 | 10 | (19) | 25† |
| Comprehensive loss | (47,641) | (49,184) | (47,070) | (41,070)† | (26,877) | (18,468) | (24,847) | (19,474)† |
| Net loss per share — basic (in USD per share) | (2.03) | (2.34) | (2.25) | — | (1.30) | (0.89) | (1.50) | — |
| Net loss per share — diluted (in USD per share) | (2.03) | (2.34) | (2.25) | — | (1.30) | (0.89) | (1.50) | — |
| Weighted-average common shares used to compute net loss per share - basic (in shares) | 23,487 | 21,010 | 20,938 | — | 20,876 | 20,852 | 16,479 | — |
| Weighted-average common shares used to compute net loss per share - diluted (in shares) | 23,487 | 21,010 | 20,938 | — | 20,876 | 20,852 | 16,479 | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.